KBC Group
AGIO icon

KBC Group’s Agios Pharmaceuticals AGIO Stock Holding History

KBC Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77K Hold
2,073
– – ﹤0.01% 1544
2026
Q1 		$70K Sell
2,073
-947
-31% -$26.8K ﹤0.01% 1504
2025
Q4 		$82K Buy
3,020
+1,269
+72% +$44.5K ﹤0.01% 1408
2025
Q3 		$70K Hold
1,751
– – ﹤0.01% 1481
2025
Q2 		$58K Sell
1,751
-864
-33% -$26.2K ﹤0.01% 1530
2025
Q1 		$77K Hold
2,615
– – ﹤0.01% 1615
2024
Q4 		$86K Buy
2,615
+611
+30% +$28.7K ﹤0.01% 1641
2024
Q3 		$89K Hold
2,004
– – ﹤0.01% 1357
2024
Q2 		$86K Buy
+2,004
New +$72.3K ﹤0.01% 1255

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

KBC Group's AGIO Position: Q2 2026 in Review

KBC Group held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 2,073 shares worth $77K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

KBC Group first reported a position in AGIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $89K in Q3 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • KBC Group held 2,073 shares of Agios Pharmaceuticals worth $77K as of Q2 2026.
  • KBC Group left its Agios Pharmaceuticals share count unchanged in Q2 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1544 holding.
  • KBC Group first reported a position in Agios Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • KBC Group's Agios Pharmaceuticals position peaked at $89K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.